KB002 / Humanigen - LARVOL DELTA

EphA3-Expressing Lung Cells Contribute to Fibrosis in IPF (ATS 2019) - "...Nintedanib is a multi-tyrosine kinase inhibitor, which is now used clinically but patients on this medication still exhibit the loss of lung function indicating that other mechanisms might not be impacted by this therapeutic...Finally, targeting EphA3 expressing cells using an ADCC-inducing afucosylated anti-EphA3 antibody (i.e. KB004) ameliorated the fibrotic response at day 63 in NSG mice humanized with IPF lung cells compared with humanized NSG treated with a control IgG (KB00243) (See adjacent Figure)...Finally, targeting these cells using an ADCC-inducing afucosylated anti-EphA3 antibody ameliorated lung remodeling in NSG mice humanized with IPF explant cells. We conclude that EphA3 represents an attractive therapeutic target in IPF.Funding Sources: Cedars-Sinai Medical Center, NIH (HL123899)."